

## Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival

Cheng Tan, Tatsuya Takayama, Naohisa Takaoka, Hiromi Fujita, Miki Miyazaki,  
Takayuki Sugiyama and Seiichiro Ozono

Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

### ABSTRACT

**OBJECTIVE:** To investigate the relationship between gender differences in fatty acid-binding protein7 (FABP7) and BRN2 (POU class 3 homeobox 2) expression in renal cell carcinoma (RCC) and the prognosis of patients with RCC.

**MATERIALS AND METHODS:** immunohistochemical (IHC) staining as well as reverse transcription-polymerase chain reaction (RT-PCR) was performed in renal tissues from 103 patients (83 men, mean age = 63.6 years old; 20 women, mean age = 63.1 years old) underwent radical nephrectomy from January 1, 2001 through December 31, 2010. The probability of overall patient survival was estimated using the Kaplan-Meier method.

**RESULTS:** FABP7 mRNA expression was more frequent in men ( $P = 0.07$ ) while BRN2 protein expression was significantly more frequent in women ( $P = 0.029$ ). In particular, FABP7 was expressed in 100% of G1 renal cell carcinoma both in mRNA and protein levels. In women, FABP7 (-) and BRN2 (+) groups had a worse prognosis both in mRNA level ( $P = 0.038$ ) and protein level ( $P = 0.058$ ). BRN2 was expressed 100% of papillary RCC both in mRNA and protein levels.

**CONCLUSIONS:** Our results demonstrated that gender was a key factor in FABP7 and BRN2 expression in RCC, and the combination with FABP7 and BRN2 stratified by gender could be a new potential prognostic factor in patients with RCC.

**KEYWORDS:** BRN2, FABP7, gender, overall survival, renal cell carcinoma

**CITATION:** Tan et al. Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival. *Clinical Medicine Insights: Oncology* 2014;8:21–27 doi: 10.4137/CMO.S13684.

**RECEIVED:** November 20, 2013. **RESUBMITTED:** January 9, 2014. **ACCEPTED FOR PUBLICATION:** January 10, 2013.

**ACADEMIC EDITOR:** William C S Cho, Editor in Chief

**TYPE:** Original Research

**FUNDING:** This work was supported by funding from a Grant-in-Aid for Scientific Research (C) 23592329 from The Ministry of Education, Culture, Sports, Science and Technology of Japan.

**COMPETING INTERESTS:** Author(s) disclose no potential conflicts of interest.

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

**CORRESPONDENCE:** [tancheng@hama-med.ac.jp](mailto:tancheng@hama-med.ac.jp).

### Introduction

In 2013, a total of 580,350 cancer deaths (306,920 in males and 273,430 in females) are projected to occur in the United States, while in kidney and renal pelvis cancer, 13,680 cancer deaths (8780 in males and 4900 in females) are projected.<sup>1</sup> It is significant that the men to women ratio of patients with projected new occurrence of renal cell carcinoma (RCC) and renal pelvis carcinoma are much higher than carcinoma in general (Pearson chi-square,  $P < 0.01$ ). Similarly, according to the data from National Cancer Center, Japan, the RCC mortality in men is 3 times higher than in women. It is reported

that gender independently influenced disease-specific survival (DSS) and overall survival (OS) with a benefit for women. While men often present with high grade tumors and simultaneous metastasis,<sup>2</sup> estrogen receptor beta (ER $\beta$ ) was more highly expressed in RCC cell lines than in breast cancer cell lines and played a role as a tumor suppressor in RCC cell lines.<sup>3</sup>

It has been demonstrated that the expression level of fatty acid-binding proteins (FABPs) and POU domain-containing family of transcription factors are influenced by gender.<sup>4–9</sup> FABPs are abundant 14–16 kDa cytoplasmic proteins expressed



in almost all mammalian tissues involved in the uptake and intracellular trafficking of fatty acids. Fatty acid-binding protein 7 (FABP7), also known as brain-type fatty acid-binding protein (B-FABP), mapped to 6q22–23, is a member of FABPs, which was reported to be expressed in the brain, glia cells, retina, and mammary glands.<sup>10</sup> It is demonstrated that the expression of transcript for *FABP7* can be in tumors and/or urine of patients with RCC,<sup>11–13</sup> though protein expression is not always congruent with mRNA expression in prostate, bladder, and kidney cancer cell lines.<sup>14,15</sup> Moreover, it was recently shown that FABP7 may regulate the invasiveness of astrocytoma tumors.<sup>16</sup> Also, the POU domain-containing family of transcription factors contains multiple mammalian members divided into 6 classes, which can be expressed broadly or in a cell-specific manner and involved in regulators of cell fate decisions of many different lineages. BRN2, which is encoded by the *POU3F2* gene in humans,<sup>17</sup> is expressed predominantly in the central nervous system (CNS) and has been implicated with tumorigenesis in melanoma and lung cancer.<sup>18–22</sup> What's more, the Pbx/POU binding site has been demonstrated to be present in the *FABP7* promoter in humans, and Pbx/knotted homeobox 1 (PKNOX1) is bound to the *Pbx/POU* site at the *FABP7* promoter to regulate *FABP7* transcription.<sup>23</sup> In a previous study, we found that there was an inverse correlation between *FABP7* promoter activity and *BRN2* mRNA expression as BRN2 was bound to the *FABP7* promoter region in human RCC cell lines.<sup>24</sup>

The present investigation was conducted to examine the relationship between clinical and pathological differences, especially focused on the gender difference in FABP7 and

BRN2 expression in renal cell carcinoma and the prognosis of patients with RCC.

## Material and Methods

**Subjects.** The samples were surgically removed under radical nephrectomy from 103 RCC patients at Hamamatsu University School of Medicine during the period from January 1, 2001 through December 31, 2010. Cases were selected according to tissue availability without any further stratification for clinical or pathological prognostic factors. Staging and histological classification met the 2009 Union for International Cancer Control criteria and World Health Organization criteria, respectively. The pathologic diagnosis was based on the General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma proposed by the Japanese Urological and Pathological Association<sup>25</sup> (Table 1). This study was approved by the medical ethics committee of the Hamamatsu University Medical School.

**Immunohistochemistry.** Slices with 4- $\mu$ m thickness were used for immunohistochemical (IHC) staining. Slices were deparaffinized in xylene for 15 minutes, rehydrated using graded ethanol, and steamed for 4 minutes at 121 °C in a buffer with (10 mM sodium citrate, pH 6.0, with 1 mM EDTA) in a pressure boiler. Slides were left in the pressure boiler to cool down to 90 °C and then left for 1 hour at room temperature. The detection was done according to the protocol of Ultra Vision LP Detection System HRP Polymer and DAB Plus Chromogen kit (catalog number TL-015-HD, Thermo Scientific, Fremont, CA). For FABP7, slides were incubated overnight with a 1:100 dilution of the polyclonal antibody for

**Table 1.** Clinicopathological parameters (percentages in brackets) and mRNA and protein expression of FABP7 and BRN2 in renal cell carcinomas.

		TOTAL	FABP7 POSITIVE		BRN2 POSITIVE	
			mRNA	PROTEIN	mRNA	PROTEIN
All cases		103(100)	86(83.5)	73(70.9)	67(65.0)	72(69.9)
Age		30–87				
Mean		63.5				
Gender	Male	83(80.6)	72(86.7)	58(69.9)	52(62.7)	54(65.1)
	Female	20(19.4)	14(70.0)	15(75.0)	15(75.0)	18(90.0)
Histology	Clear cell	89(86.4)	75(84.3)	66(74.2)	54(60.7)	59(66.3)
	Papillary	6(5.8)	6(100)	3(50.0)	6(100)	6(100)
	Chromophobe	8(7.8)	5(62.5)	4(50.0)	7(87.5)	7(87.5)
Japan Grading	G1	9(8.7)	9(100)	9(100)	7(77.8)	7(77.8)
	G2	76(73.8)	62(81.6)	50(65.8)	47(61.8)	52(68.4)
	G3	18(17.5)	15(83.3)	14(77.8)	13(72.2)	13(72.2)
Stage	I	70(70.0)	61(87.1)	54(77.1)	43(61.4)	50(71.4)
	II	9(8.7)	6(66.7)	5(55.6)	7(77.8)	7(77.8)
	III	10(9.7)	9(90.0)	7(70.0)	8(80.0)	5(50.0)
	IV	14(13.6)	10(71.4)	7(50.0)	9(64.3)	10(71.4)



FABP7 (catalog number HPA028825, Sigma-Aldrich, Inc, Stockholm, Sweden) in phosphate-buffered saline at 4 °C. For BRN2, slides were incubated overnight with a 1:300 dilution of the polyclonal antibody for BRN2 (catalog number GTX114650, GeneTex, San Antonio, TX) in phosphate-buffered saline at 4 °C. For controls, formalin-fixed, paraffin-embedded sections of neuroglioma served as a positive control for FABP7, while fixed melanoma was used as a control for BRN2 (materials from Department of Dermatology and Neurosurgery, Hamamatsu University School of Medicine). Negative control slides were processed with each slide run and excluded the primary antibody but included all other steps of the procedure.

**Scoring methods.** Positive tumor cells were quantified by 2 independent observers at × 400 magnification under microscope, expressed as the percentage of the total number of tumor cells, and assigned to 1 of 5 categories numbered from 0 to 4: (0) ≤5%; (1) 5% to 25%; (2) 25% to 50%; (3) 50% to 75%; and (4) ≥75%. For both oncoproteins, ≤5% positive cells were used as the cutoff to define negative tumors. The intensity of FABP7 and BRN2 immunostaining was scored as (a) 1+, weak; (b) 2+, moderate; and (c) 3+, intense. The percentage of positivity of tumor cells and staining intensity were multiplied to produce a weighted score for each tumor specimen, and intensity was judged relative to an intensely stained positive control neoplasm.<sup>26</sup> For each slide, at least 4 fields of the cancerous parts were examined and the average value determined. Every slide was rechecked by a veteran doctor. Cases with weighted scores of less than 1 were defined as negative; otherwise, they were defined as positive. We divided the weighted scores of 0 to 2 as negative or low group and marked as ws- and 3 to 12 as moderate and high group and marked as ws+.

**Reverse transcription-polymerase chain reaction (RT-PCR).** Total RNA was isolated from surgically resected tissues using AllPrep DNA/RNA/Protein Mini Kit (catalog number 80004, Qiagen, GmbH, Hilden, Germany). First-strand

cDNA was synthesized in a volume of 35 µL containing 1 µg total RNA, 0.7 µL oligo(dT)12–18 primer (catalog number 18418012, Life Technologies, Carlsbad, CA), 1.8 µL random primers (catalog number 48190011, Life Technologies, Carlsbad, CA), and 2.5 µL 10 mM dNTP MIX (catalog number 18427088, Life Technologies, Carlsbad, CA). After 5 minutes at 65 °C, then 2 minutes on ice, this was mixed with a volume of 15 µL reagent of SuperScript III kit (catalog number 18080–044, Life technologies, Carlsbad, CA). A polymerase chain reaction (PCR) was performed using polymerase Ex Taq (Takara Bio Inc, Shiga, Japan) with Gene Amp PCR system 9700 (Life Technologies, CA). The PCR product was analyzed by 2% agarose gel electrophoresis, and β-actin served as an internal control (Table 2). cDNA isolated from a TUHR14TKB cell line (RIKEN, Tsukuba, Ibaraki, Japan) was used as a positive control for FABP7, and HEK 293 (RIKEN, Tsukuba, Ibaraki, Japan) was used as a positive control for BRN2. A negative control was processed with each run and used the same volume of distilled water instead of samples cDNA but included all other steps of the procedure.

**Statistical analysis.** Quantitative variables were compared by using chi square test, and the probability of overall patient survival was estimated using the Kaplan-Meier method. Statistical analysis was performed with SPSS, version 19.0 (IBM Japan, Tokyo, Japan). *P* values <0.05 were considered significant.

## Results


**Reverse transcription-polymerase chain reaction (RT-PCR).** In general, there was no relationship in *FABP7* mRNA expression (log-rank test, *P*=0.55) and *BRN2* expression (log-rank test, *P* = 0.19) with overall survival, respectively. There was *FABP7* mRNA expression in 100% of G1 RCC.

By gender, *FABP7* expression was more frequent in men (Pearson chi-square, *P* = 0.07), while *BRN2* mRNA expression had no correlation with gender (Pearson chi-square, *P* = 0.30).

**Table 2.** Primers used for the PCR-amplification.

	LENGTH	SEQUENCES	CONDITION
FABP7A	339bp	forward: 5 'TGACCAACAGTCAGAACTTT 3', reverse: 5 'ACATACCAAAAAGTAAGGGT 3'	30 seconds at 96 °C, 20 seconds at 54 °C, 20 seconds at 72 °C for 42 cycles
FABP7B	294bp	forward: 5 'GTGGGAAATGTGACCAAACC 3', reverse: 5 'CTCATAGTGGCGAACAGCAA 3'	30 seconds at 96 °C, 20 seconds at 62 °C, 20 seconds at 72 °C for 35 cycles
FABP7C	270bp	forward: 5 'GACCAACAGTCAGAACTTT 3', reverse: 5 'GCCATCCCATTCTGTATGTG 3'	20 seconds at 96 °C, 20 seconds at 54 °C, 1 minute at 72 °C for 35 cycles
BRN2	216bp	forward: 5 'CGGCGGATCAAACCTGGGATTT 3', reverse 5 'TTGCGCTGCGATCTTGCTAT 3'	30 seconds at 94 °C, 30 seconds at 54 °C, 30 seconds at 72 °C for 35 cycles
β-actin	353bp	forward: 5 'CAAACATGATCTGGGTCATCTTCTC 3', reverse 5 'GCTCGTCGTCGACAACGGCTC 3'	30 seconds at 94 °C, 30 seconds at 56 °C, 30 seconds at 72 °C for 35 cycles

**Note:** A case was considered as *FABP7* positive once it showed positive in a random primer among the three pairs of *FABP7* primers.



**Figure 1.** FABP7 and BRN2 immunohistochemistry.

(A) In normal tissue, FABP7 is preferentially expressed in the proximal tubuli. (B) In carcinomas tissue, FABP7 can be expressed in any part of the cell. (C) In normal tissue, BRN2 is expressed in all parts and can be strongly expressed in a few tubuli. (D) In carcinomas tissue, BRN2 is preferentially expressed in the nucleus.

*FABP7* (–) and *BRN2* (+) group in women had a worse prognosis (log-rank test,  $P = 0.038$ ) (Fig. 2A), and there were only 2 women in high stage (stage 3 or 4), and these 2 women were both *FABP7* (–) and *BRN2* (+) in mRNA level, while in men, there was no relationship (log-rank test,  $P = 0.72$ ). In women, 5 were classified as *BRN2* (–), and all in low stage (stage 1 or 2), and all have survived until now, while in men, there was no relationship in *BRN2* expression with overall survival (log-rank test,  $P = 0.31$ ).

In all, 100% of papillary RCC could express *FABP7* and *BRN2*, and clear cell RCC (ccRCC) was more frequently *BRN2* (–) compared with the other histology type groups (Pearson chi-square,  $P = 0.019$ ).

We had 89 ccRCC patients, and among these, 5 patients (5/89, 5.6%) were *FABP7* (–) and *BRN2* (–), and all have survived. However, *FABP7* and *BRN2* were not significantly associated with overall survival (log-rank test,  $P = 0.68$  and  $P = 0.36$ , respectively).


**Immunohistochemistry (IHC).** In normal renal tissue, *FABP7* showed a weak immunoreactivity in proximal tubuli. Few distal tubuli were also inconsistently positive. No immunoreactivity was observed in glomeruli (Fig. 1A). Among 74 patients with *FABP7* expression (71.8%), some carcinoma cells were expressed in the nucleus (57/74, 77.0%), some in the cytoplasmic (53/74, 71.6%), and some in the membrane (48/74, 64.9%) (Fig. 1B).

*BRN2* is weakly expressed in the cytoplasmic and membrane of almost all renal tubuli (including proximal tubuli and distal convoluted tubuli), and in the glomeruli, few tubuli can strongly express *BRN2* in membrane (3+, intense) in normal tissue (Fig. 1C). Among 72 patients with *BRN2* expression (69.9%), some carcinoma cells expressed in nucleus (55/72, 76.4%), some in cytoplasmic (14/72, 19.4%), and some in membrane (15/72, 20.8%) (Fig. 1D).

In general, there was no relationship between overall survival and *FABP7* protein expression (log-rank test,  $P = 0.99$ ) and *BRN2* expression (log-rank test,  $P = 0.81$ ), respectively. There was *FABP7* protein expression in 100% of G1 RCC. Of 12 patients with an *FABP7* weighted score  $\geq 9$ , only 1/12 (8.3%) died of RCC, with the remaining 11 patients still surviving; 5 patients with a *BRN2* weighted score  $\geq 9$  also survived.

By gender, *BRN2* was significantly easier to express in women (Pearson chi-square,  $P = 0.029$ ), while *FABP7* expression had no correlation with gender (Pearson chi-square,  $P = 0.65$ ). Women with *FABP7* (–) and *BRN2* (+) had a tendency for a worse prognosis (log-rank test,  $P = 0.058$ ) (Fig. 2B), while men in this group had no correlation with overall survival (log-rank test,  $P = 0.13$ ).

In men, there were 10 patients (10/83, 12.0%) with *FABP7* (ws–) and *BRN2* (ws+), and all survived (Fig. 3A). In



**Figure 2.** Kaplan-Meier survival curves for FABP7 (-) and BRN2 (+) mRNA and protein expression in women.

FABP7 (-) and BRN2 (+) group (green line) revealed shorter survival times when compared with other patients (blue line) in mRNA level (**A**) and protein level (**B**). In mRNA data, there are 4 patients with FABP7 (-) and BRN2 (+), and the average survival time is 38.8 months, however, other 16 patients' average survival time is 60.0 months. In protein data, there are 5 patients with FABP7 (-) and BRN2 (+), and the average survival time is 40.7 months, while, other 15 patients' average survival time is 60.8 months.


women, there were 8 patients (8/20, 40%) with FABP7 (ws+) and BRN2 (ws+) (Fig. 3B), and all survived.

However, we didn't find any direct relationship with BRN2 protein expression and *FABP7* mRNA expression (Pearson chi-square,  $P = 0.52$ ).

There was no relationship with stage (stages 1 and 2 were recognized as low stages, while stages 3 and 4 were recognized as high stages) and FABP7 mRNA/protein

expression (Pearson chi-square,  $P = 0.51$  and  $P = 0.12$ , respectively) and also between stage and BRN2 mRNA/protein expression (Pearson chi-square,  $P = 0.50$  and  $P = 0.37$ , respectively).

In histology, ccRCC had the tendency to be FABP7 (+) more than other histology type groups (Pearson chi-square  $P = 0.064$ ) and to be BRN2 (-) more than the other histology type groups (Pearson chi-square,  $P = 0.044$ ). However, we still



**Figure 3.** Kaplan-Meier survival curves for patients divided by protein level weighted score.

(A) In men, 10 patients in the FABP7 (ws-) and BRN2 (ws+) group (green line) survived, and the other male patients are shown by the blue line.

(B) In women, 8 patients in the FABP7 (ws+) and BRN2 (ws+) group (green line) survived, and the other female patients are shown by the blue line.

couldn't find any direct relationship between BRN2 protein expression and *FABP7* mRNA expression in ccRCC (Pearson chi-square,  $P = 0.29$ ). 100% of papillary RCC could express BRN2.

We had 89 ccRCC patients, and among them there were 10 patients (10/89, 11.2%) with FABP7 (ws-) and BRN2 (ws+), and all survived. However, FABP7 and BRN2 were not significantly associated with overall survival (log-rank test,  $P = 0.77$  and  $P = 0.56$ , respectively).

## Discussion

Our study is the first to analyze the FABP7 and BRN2 mRNA and protein expression in all 103 patients with RCC and found men more frequently had *FABP7* mRNA expression, while in women BRN2 protein expression was significantly frequent. So, we have reason to believe FABP7 and BRN2 expression is affected by gender.

It is reported that hepatic removal of long-chain fatty acids from plasma is nearly twice as fast in women's livers as in men's livers.<sup>5</sup> And FABPs are involved in the uptake and intracellular trafficking of fatty acids. Niizeki et al<sup>4</sup> found 1

FABPs member, FABP3, had mean values that were significantly higher in men than in women when they did serum examination of 2099 normal participants in Takahata, Japan. Furthermore, an analysis of human glial astrocytomas and melanoma found that patient survival was inversely correlated with FABP7 expression level when using gender-mixed data,<sup>27-30</sup> while there was a positive correlation in women only with breast cancer from 899 primary operable invasive breast carcinoma cases.<sup>6</sup> It is possible that FABPs move into the nucleus and interact with nuclear hormone receptors.<sup>10,31</sup> Ilija et al<sup>7</sup> found a POU3 domain transcription factor, Oct-6, had a lower expression level in cortical and cerebellar tissue of male CD1 mice when compared with females and suggested Oct-6 expression takes place in a gender-dependent way. What's more, another POU domain transcription factor, BRN3b can physically interact directly with the estrogen receptor (ER), and enhance its transcriptional effect on an ER element-containing promoter in breast cancer.<sup>8,9</sup>

Tolle et al<sup>11</sup> found RCC with a high tumor Fuhrman grading (grades 3 and 4) showed significantly lower *FABP7* mRNA compared with those with a low grading (grades 1 and 2) when quantitative RT-PCR was performed. In our study, using Japan grading, we found FABP7 expression in 100% of G1 RCC in mRNA and protein levels, and among patients with FABP7 weighted score  $\geq 9$ , 11/12 (91.7%) survived. It was demonstrated that FABP7 is more frequently expressed in lower nuclear gradings, and high weighted score patients will have a better prognosis.

We found female patients with FABP7 (-) and BRN2 (+) had a worse prognosis both in mRNA, protein level, and mRNA clinical data (there were only 2 women in high stage, and both belong to this group in mRNA level). On the other hand, male patients with FABP7 (ws-) and BRN2 (ws+) all survived. It may be that FABP7 (-) and BRN2 (+) can be a potential prognosis factor in patients with RCC stratified by gender, and the system of these 2 proteins is different by gender in patients with RCC.

In the previous study, we found that there was an inverse correlation between *FABP7* promoter activity and *BRN2* mRNA expression in an RCC cell line,<sup>24</sup> while we couldn't find the relationship in the 103 RCC patients or in all 89 ccRCC patients. However, ccRCC is more frequently FABP7 (+) than other histology type groups in protein level and BRN2 (-) in both mRNA and protein levels. Thus, some relationship may exist between FABP7 and BRN2 in ccRCC in clinical data, but it may also be influenced by other factors not examined here.

In our study, FABP7 and BRN2 had no relationship with overall survival both in mRNA and protein levels in all 103 patients with RCC or 89 patients with ccRCC respectively, similar to the result of FABP7 expression in patients with RCC in a previous study.<sup>11</sup> However, our study suggests that FABP7 or BRN2 could have a prognostic potential at least in combination with other biomarkers.

It has been demonstrated that there is a method by which FABP7 can be detected in the urine of patients with RCC.<sup>12</sup> If there also will be a method to detect BRN2, FABP7/BRN2 can be used to potentially monitor the prognosis of patients with RCC preoperatively and postoperatively in the near future.

## Conclusions

Our results demonstrated gender was a key factor in FABP7 and BRN2 expression in patients with RCC, and FABP7 binding with BRN2 stratified by gender could be a new potential survival predictor in patients with RCC. Our study is the first report on both FABP7 and BRN2 mRNA and protein expression in patients with RCC. Further study is warranted with regard to interpreting the relationship between sex hormones with FABP7 and BRN2 in patients with RCC.

## Acknowledgment

We thank Mr. Gregory O'Dowd, Integrated Human Sciences (English), Hamamatsu University School of Medicine, for proofreading this paper.

## Author Contributions

Conceived and designed the experiments: CT, TT. Analyzed the data: CT. Wrote the first draft of the manuscript: CT. Contributed to the writing of the manuscript: TT, NT, SO. Agree with manuscript results and conclusions: CT, TT, NT, HF, MM, TS, SO. Jointly developed the structure and arguments for the paper: TT, NT, TS. Made critical revisions and approved final version: CT, TT, NT, HF, MM, TS, SO. All authors reviewed and approved of the final manuscript.

## DISCLOSURES AND ETHICS

As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

## REFERENCES

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin*. 2013;63:11–30.
2. May M, Aziz A, Zigeuner R, et al. Members of the CORONA project the Young Academic Urologists Renal Cancer Group. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. *World J Urol*. 2013;31(5):1073–80.
3. Yu CP, Ho JY, Huang YT, et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. *PLoS One*. 2013;8:e56667.
4. Niizeki T, Takeishi Y, Takabatake N, et al. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. *Circ J*. 2007;71:1452–7.
5. Hagve TA, Christensen E, Grønn M, Christophersen BO. Regulation of the metabolism of polyunsaturated fatty acids. *Scand J Clin Lab Invest Suppl*. 1988;191:33–46.
6. Zhang H, Rakha EA, Ball GR, et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. *Breast Cancer Res Treat*. 2010;121:41–51.
7. Ilija M, Sugiyama Y, Price J. Gender and age related expression of Oct-6—a POU III domain transcription factor, in the adult mouse brain. *Neurosci Lett*. 2003;344:138–40.
8. Dennis JH, Budhram-Mahadeo V, Latchman DS. The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells. *Oncogene*. 2001;20:4961–71.
9. Lee SA, Ndisang D, Patel C, et al. Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. *Cancer Res*. 2005;65:3072–80.
10. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. *Nat Rev Drug Discov*. 2008;7:489–503.
11. Tolle A, Jung M, Lein M, et al. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? *BMC Cancer*. 2009;9:248.
12. Teratani T, Domoto T, Kuriki K, et al. Detection of transcript for brain-type fatty acid-binding protein in tumor and urine of patients with renal cell carcinoma. *Urology*. 2007;69:236–40.
13. Domoto T, Miyama Y, Suzuki H, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. *Cancer Sci*. 2007;98:77–82.
14. Tolle A, Suhail S, Jung M, Jung K, Stephan C. Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. *BMC Cancer*. 2011;11:302.
15. Tolle A, Krause H, Miller K, Jung K, Stephan C. Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. *Oncol Rep*. 2011;25:1307–12.
16. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R. B-FABP-expressing radial glial cells: the malignant glioma cell of origin? *Neoplasia*. 2007;9:734–44.
17. Schreiber E, Tobler A, Malipiero U, Schaffner W, Fontana A. cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif. *Nucleic Acids Res*. 1993;21:253–8.
18. Goodall J, Martinozzi S, Dexter TJ, et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. *Mol Cell Biol*. 2004;24:2915–22.
19. Thomson JA, Murphy K, Baker E, et al. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. *Oncogene*. 1995;11:691–700.
20. Eisen T, Easty DJ, Bennett DC, Goding CR. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. *Oncogene*. 1995;11:2157–64.
21. Schreiber E, Himmelmann A, Malipiero U, Tobler A, Stahel R, Fontana A. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2). *Cancer Res*. 1992;52:6121–4.
22. Ishii J, Sato H, Sakaeda M, et al. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer. *Pathol Int*. 2013;63:158–68.
23. Sanchez-Font MF, Bosch-Comas A, Gonzalez-Duarte R, Marfany G. Overexpression of FABP7 in Down syndrome fetal brains is associated with PKNOX1 gene-dosage imbalance. *Nucleic Acids Res*. 2003;31:2769–77.
24. Takaoka N, Takayama T, Teratani T, Sugiyama T, Mugiya S, Ozono S. Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines. *BMC Mol Biol*. 2011;12:31.
25. The Japanese Urological Association, The Japanese Society of Pathology, Japan Radiological Society. *General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma*. 4th ed. Tokyo, Japan: Kanehara; 2011.
26. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. *Cancer Res*. 1995;55:237–41.
27. Goto Y, Koyanagi K, Narita N, et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. *J Invest Dermatol*. 2010;130:221–9.
28. Kaloshi G, Mokhtari K, Carpentier C, et al. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. *J Neurooncol*. 2007;84:245–8.
29. Goto Y, Matsuzaki Y, Kurihara S, et al. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. *Cancer Res*. 2006;66:4443–9.
30. Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. *BMC Cancer*. 2006;6:97.
31. Glatz JF, Storch J. Unravelling the significance of cellular fatty acid-binding proteins. *Curr Opin Lipidol*. 2001;12:267–74.